49011-0

LOINC code 49011-0 identifies "Platelet aggregation [Units/volume] in Platelet rich plasma by arachidonate induced". A whole blood assay for detecting platelet inhibition or dysfunction due to aspirin therapy. This in vitro assay uses citrated whole blood in the point of care or laboratory setting. Not for use in patients with underlying congenital platelet abnormalities, patients with non-aspirin induced acquired platelet abnormalities or in patients receiving non-aspirin platelet agents (may be used in patients treated with COX-2 inhibitors, e.g., (Celebrex(r))). The VerifyNow assay incorporates the agonist arachidonic acid to activate platelets, and measures platelet function based upon the ability of activated platelets to bind fibrinogen. Fibrinogen-coated microparticles aggregate in whole blood in proportion to the number of unblocked platelets GP IIb/IIIa receptors. Light transmittance increases in as activated platelets bind and aggregate fibrinogen-coated beads. The instrument measures this change in optical signal caused by aggregation. Information from VerifyNow Aspirin Assay package insert from www.Accumetrics.com accessed 2090618.

This code measures Platelet aggregation in PRP. It belongs to the COAG class in the LOINC classification.

LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying laboratory and clinical observations. It is maintained by the Regenstrief Institute and used worldwide for health data exchange.